ABBV Jan 2025 240.000 call
| Previous close | 0.1900 |
| Open | 0.0900 |
| Bid | 0.1000 |
| Ask | 0.2800 |
| Strike | 240.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0900 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 136 |
- Yahoo Finance Video
FTC warns pharma companies on excessive drug patenting
The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
- Yahoo Finance Video
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
ReutersAbbVie's $8.7 billion bet on Cerevel is risky but smart, analysts say
AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said. North Chicago, Illinois-based AbbVie said late Wednesday it would buy Cerevel for $8.7 billion, gaining a portfolio of drugs being tested for a range of neurological conditions, including emraclidine for schizophrenia. "Boldly buying Cerevel now avoids a possible bidding war post-data," Stifel analysts wrote in a note.
